Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Approvals/Health Canada/REKOVELLE

Authorized

STANDARD

REKOVELLE

Ferring Inc🇨🇦 Health Canada

Approval Date: Jul 4, 2025
Approval ID: c629d7b216a7b754
Company: Ferring Inc
Type: Standard

Approval Details

Approval Id: c629d7b216a7b754
Drug Approval Canada Name: REKOVELLE
Product Name: REKOVELLE
Status: Marketed
Status Date: 2019-11-01
Original Market Date: 2019-11-01
Din: 02487489
Drug Class: Human
Dosage Form: Solution
Route Of Administration: Subcutaneous
Schedule: Prescription , Schedule D
Ahfs: 68:18.00
Atc Original: G03GA10 FOLLITROPIN DELTA
Atc Name: g 03 ga 10
Aig Number: 0160130001
Company Name: Ferring Inc
Company Address: 500, 200 Yorkland Blvd, Toronto, Ontario, Canada, M2J 5C1

Active Ingredients

FOLLITROPIN DELTA

72 MCG / 2.16 ML

Authorized

Quick Info

Agency

Health Canada

Country

🇨🇦

Approval Date

Jul 4, 2025

Approval ID

c629d7b216a7b754

Type

Standard

Back to Health Canada Approvals

REKOVELLE - Health Canada Drug Approval Details